Drug targets

In the UK, a University of Manchester-led team of scientists has discovered that the most common form of adult blindness is probably caused by a failure of at least one of five proteins to regulate the immune system. The breakthrough could one day herald the development of transformative treatments for developing age-related macular degeneration (AMD), […]

A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON bridges the gap in the […]

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK is poised to take further […]

The process of antibody discovery and development into a clinical candidate is one full of twists, turns and offshoots, yet one that an increasing number of researchers and companies, both small and large, have successfully navigated. This eBook released by Twist Biopharma is designed to be used as a handbook for the modern antibody development […]

Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells in vitro, there is now […]

Macrophages are involved in many different disease states, so understanding more about how these cells are regulated is important for future therapies for a range of diseases.  CD14, a co-receptor for bacterial lipopolysaccharide, and can potentiate inflammatory signalling when upregulated on myeloid cells during differentiation. Join DDW for this webinar, A new path to the […]

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Proctor explains that Genovac, a […]

The first outcome of the Optibrium and BioPharmics collaboration will be a new module for StarDrop, Optibrium’s small molecule design, optimisation and analysis software,. The new Surflex eSim 3D module, planned for the third quarter of 2021, will leverage BioPharmics’ three-dimensional (3D) ligand-based design approaches, offering exceptional virtual screening and compound design capabilities for targets […]

Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within the drug discovery and development process providing researchers with information that can help identify potential drug targets or see how drugs are working. Developments in […]

Now a key pillar in the early stages of therapeutics development, the limitations of introducing a DNA double strand break mean that workflows are broadening away from CRISPR–Cas as a gene knockout technology and towards platforms that enable genetic modulation and safer genetic alterations. Nicola McCarthy, Horizon Discovery, explains. Navigating from target identification to validation […]